Clinical trial
Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes (EQoL-MDS)
NCT02912208 is registered in ClinicalTrials.gov with Associazione Qol-one as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes (EQoL-MDS)
- Lead sponsor
- Associazione Qol-one
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- June 11, 2011
- Completion date
- October 31, 2026
- Enrollment
- 174 (estimated)
- Sites
- 64
Conditions
As the registry lists them; a condition with its own page is linked.